Rigel Pharmaceuticals
Rigel Pharmaceuticals

Rigel Pharmaceuticals

Biotechnology
WebsiteInvestor RelationsSEC
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

$916.8M

Market Cap • 10/9/2026

1996

(30 years)

Founded

2000

(26 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2,2

P/S

3,3

P/EBITDA

10,2

P/OCF

11,5

P/FCF

11,5

P/E

3

BVPS

22,8

EPS

16,5

Market Cap

Market Cap

916,8M

EV

861,4M

EV/Revenue

3,1

EV/EBITDA

9,6

EV/EBIT

9,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,6%

Total Yield

-0,6%

Payout

0%

Retained Earnings

-997,1M

Profitability

Gross Margin

91,4%

EBITDA Margin

32,4%

EBIT Margin

31,5%

Net Margin

116,3%

D&A/EBITDA

0%

R&D/Revenue

15,8%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

20,7%

% PPE

0,1%

% Goodwill

0%

ROE

126,9%

ROIC

40,5%

Growth

CAGR Revenue 5Y

13,9%

CAGR OCF 5Y

228,7%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

1,9

Quick Ratio

1,6

Interest Coverage

1499,6%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium